Several CVOTs have confirmed that treatment with SGLT2 inhibitors consistently reduces the risk of HF-related events in patients who had previously been taking glucose-lowering agents, including metformin [14–16]. This evidence concerns the gene SLC5A2 and hydrops fetalis.